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dasatinib have different side effect proﬁles. The aim of this
study was to investigate costs of adverse events (AEs) in
patients receiving recommended doses of nilotinib or dasatinib
for treatment of chronic and accelerated CML. METHODS:
Incidence rates of grade 3/4 AEs in CML patients treated with
nilotinib or dasatinib were obtained from clinical trial data.
Direct medical costs for non-hematological AEs and for grade 4
anemia and thrombocytopenia, and febrile neutropenia were
obtained from Ontario Case Costing Initiative (OCCI) inpatient
databases and were speciﬁc to oncology patients. Costs for
grade 3 anemia, thrombocytopenia, and non-febrile neutrope-
nia were assumed to be outpatient costs and were based on
literature and expert validation of treatment pathway and
resource utilization in the Canadian context. Multivariate sen-
sitivity analyses were conducted on costs of AEs and for an
alternative dasatinib dosing (100 mg). RESULTS: Cost of
treatment-related AEs for CML patients was highest for dasa-
tinib. Total costs for AEs associated with the accelerated phase
were higher than those associated with the chronic phase:
$19,902 versus $7,653 for dasatinib and $8,645 versus $3,790
for nilotinib, respectively. Ranking observed among treatments
for base case costs of AEs was maintained for both high and
low cost estimates, and for 100 mg dasatinib dosing, indicating
that the model was robust to variation in these parameters.
CONCLUSION: For patients resistant or intolerant to ima-
tinib, costs of dasatinib-related AEs were approximately twice
the costs of nilotinib-related AEs in both chronic and acceler-
ated phases, highlighting the importance of considering the cost
of AEs in economic evaluation of tyrosine kinase inhibitors.
Further research is needed to evaluate the impact of AEs on
health care expenditures.
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OBJECTIVES: We developed a probabilistic decision model of
cost-effectiveness for lung cancer (LC) screening with helical
computed tomography (hCT) compared with chest x-ray (CXR)
and no screening (NS) given uncertain efﬁcacy and risks of
screening in practice. METHODS: Markov model comparing NS
to CXR and hCT screening in 60-year old current smokers
screened annually until age 75 as base case using published
literature, Surveillance Epidemiology and End Results database,
and Mayo Clinic data. In the base case, we assumed stage shifts
observed with screening translate into survival beneﬁts. Sensitiv-
ity analyses evaluated cohort ages for starting and stopping
screening, screening compliance, smoking status, positive nodule
management and treatment costs. An expected value of perfect
information analysis (EVPI) was estimated to determine the value
of further research to reduce current uncertainty. RESULTS: In
the base case, CXR cost $51,245/QALY vs. NS and hCT was
dominated by CXR. The probability that CXR is cost-effective
was 94.3% at a maximum acceptable ratio of $100,000/QALY
(4.8% and 0.9% for NS and hCT, respectively). EVPI analysis
suggested that at a maximum ICER of $100,000/QALY, further
research would potentially be worth $55 million for the US
population over ten years. When it was assumed that hCT
screening did not result in any false positives necessitating
invasive surgery, hCT cost $119,571/QALY vs. CXR. CXR cost
$137,652 vs. NS for former smokers and was dominated by NS
for never smokers; hCT was dominated in both these analyses.
Results were sensitive to age at annual screening initiation and
termination. CONCLUSIONS: Assuming stage shifts observed
with LC screening translate into survival beneﬁts, hCT was, as
expected, most efﬁcacious, but also had the highest false positive
rate. The associated detrimental cost and quality of life effects
resulted in hCT being dominated by CXR (less efﬁcacious but
more speciﬁc).
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OBJECTIVE: To examine the cost-effectiveness of introducing an
HPV-16/18 prophylactic cervical cancer (CC) vaccine in a setting
of existing screening in Portugal. METHODS: A Markov cohort
simulation model was used with an annual cycle length and
which mimics the natural history of HPV infection to CC. The
analysis was undertaken from the health care system perspective.
Direct medical costs were estimated and discounted at a rate of
3%. Effect measures were: CC cases and deaths avoided, life
years saved and QALYs, discounted at a rate of 3%. The incre-
mental cost-effectiveness was estimated by comparison of the
options to be implemented with the current strategy. The analytic
horizon was lifetime where subjects enter the model at 10 years
old and are followed for 95 cycles until death. One-way sensi-
tivity analysis was conducted on the key variables. RESULTS:
Our results predicted that an HPV-16/18 vaccine targeting
12-year-old girls would be cost-effective and could reduce life-
time CC cases and mortality by 92% compared with current
screening. Vaccination was predicted to substantially reduce the
number of oncogenic HPV infections and Cervical Intraepithelial
Neoplasia cases (CIN1-3 cases). The additional cost of generat-
ing one QALY by implementing a vaccination strategy, where all
12-year-old girls are vaccinated with a vaccine showing 96.7%
efﬁcacy against HPV-16/18, was €13,810. The results were sen-
sitive to alternative assumptions about the discount rate and age
at which vaccination begins. The base-case strategy was robust to
modiﬁcations in vaccination coverage and fairly robust
to changes in both percentages of oncogenic HPV and of oppor-
tunistic screening rates. CONCLUSION: The analysis suggested
that prophylactic cervical cancer vaccination could have a sub-
stantial public health beneﬁt. A vaccine directed speciﬁcally at
reducing the incidence of oncogenic HPV types 16 and 18, during
the peak ages of infection, could be expected to be economically
attractive.
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OBJECTIVE: Determine appropriate scenarios for screening
compliance for vervical cancer in Israel. METHODS: Genera-
lised cost-effectiveness estimates of screening (PAP, HPV-DNA,
VIA at various frequencies) and/or HPV vaccination interven-
tions for cervical cancer in Israel were calculated using WHO-
CHOICE standardised methodology, utilising a state transition
population model (POPMOD) simulating Israeli population
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